Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 16/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | HTR2A | P28223 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 2/20 | 0.68 |
| ▸ | HRH1 | P35367 | 2/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.68 |
| ▸ | DRD3 | P35462 | 2/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.68 |
| ▸ | HTR2B | P41595 | 2/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085606 | 0.86 | SLC6A4 (0.75) | SLC6A4SLC6A2 | |
| SCHEMBL14085621 | 0.86 | SLC6A4 (0.75) | SLC6A4SLC6A2 | |
| SCHEMBL5078702 | 0.86 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL6268557 | 0.85 | SLC6A2 (0.73) | SLC6A4SLC6A2PMP22 | |
| Hydrochloric Acid SCHEMBL4848278 | 0.85 | SLC6A2 (0.73) | SLC6A4SLC6A2PMP22 | |
| Hydrochloric Acid SCHEMBL4851048 | 0.85 | SLC6A2 (0.73) | SLC6A4SLC6A2PMP22 | |
| Hydrochloric Acid SCHEMBL7771743 | 0.85 | SLC6A4 (0.73) | SLC6A4SLC6A2 | |
| SCHEMBL3967638 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3359634 | 0.84 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14085618 | 0.84 | SLC6A2 (0.72) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629615-B1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | UNIV DUKE (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20160374957-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | UNIV DUKE (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468627-B2 | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies | DUKE UNIVERSITY (US) | 2016-10-18 | — | — | US | disclosed |
| US-20130338192-A1 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS | DUKE UNIVERSITY (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130230577-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | DUKE UNIVERSITY (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2629615-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | Duke University (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012054815-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | DUKE UNIVERSITY (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20090192166-A1 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS | DUKE UNIVERSITY (US) | 2009-07-30 | — | — | US | disclosed |
| US-7517908-B2 | Method for augmenting the effects of serotonin reuptake inhibitors | DUKE UNIVERSITY (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1746985-A2 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS | DUKE UNIVERSITY (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060142375-A1 | Method for augmenting the effects of serotonin reuptake inhibitors | DUKE UNIVERSITY | 2006-06-29 | — | — | US | disclosed |
| WO-2005112906-A2 | METHOD FOR AUGMENTING THE EFFECTS OF SEROTONIN REUPTAKE INHIBITORS | DUKE UNIVERSITY (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230577-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | TPH1, HTR5A, TPH2 | SLC6A4 13/4885SLC6A2 25/4885CYP1A2 1610/4885 |
| US-20160374957-A1 | SLOW-RELEASE FORMULATIONS OF 5-HYDROXYTRYPTOPHAN AS AN ADJUNCT TO PRO-SEROTONERGIC THERAPIES | TPH1, HTR5A, TPH2 | SLC6A4 13/4885SLC6A2 25/4885CYP1A2 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.